ANS 6637
Alternative Names: ANS-6637; GS-6637; GS-6673Latest Information Update: 05 Feb 2021
At a glance
- Originator Gilead Sciences
- Developer Amygdala Neurosciences; National Institute on Alcohol Abuse and Alcoholism; National Institutes of Health
- Class Anxiolytics; Drug withdrawal therapies
- Mechanism of Action Aldehyde dehydrogenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alcoholism; Opioid-related disorders; Smoking withdrawal; Substance-related disorders
Most Recent Events
- 28 Jan 2021 Discontinued - Phase-I for Opioid-related disorders (In volunteers) in USA (PO) (NCT04169360)
- 28 Jan 2021 Discontinued - Phase-I for Substance-related disorders in USA (PO) (NCT04169360)
- 28 Jan 2021 Discontinued - Phase-II for Alcoholism (In adults) in USA (PO) (NCT04169360)